Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:

3 patent-pending new drug families drawing on novel chemical structures;

75 compounds synthesized with preclinical data demonstrating promising results; and

Synthesis process for psilocybin demonstrating clear benefits over known processes.